Thanh bên bài viết

PDF
Ngày xuất bản: 25/11/2024
Số lượt xem tóm tắt: 30
Số lượt xem PDF: 13
DOI: https://doi.org/10.59873/vjid.v4i48.417
Số xuất bản
Tập 4 Số 48 (2024)
Chuyên mục
Nghiên cứu khoa học
Trích dẫn bài báo
Ngo, V. L., Hoang, M. C., Nguyen, T. H., Dao, T. N., Le, V. T., Le, T. T. N., Phan, N. H. M., & Duong, H. Q. (2024). PERSONALIZED MEDICINE FOR DIAGNOSIS AND TREATMENT OF NON-SMALL-CELL LUNG CANCER. Tạp chí Truyền nhiễm Việt Nam, 4(48). https://doi.org/10.59873/vjid.v4i48.417

PERSONALIZED MEDICINE FOR DIAGNOSIS AND TREATMENT OF NON-SMALL-CELL LUNG CANCER

Ngo Van Lang1,, Hoang Minh Cong2, Nguyen Thi Hue3, Dao Thi Nguyet4, Le Van Thu5, Le Thi Thanh Nhan5, Phan Nguyen Hoang Mai5, Duong Hong Quan5
1 Phenikaa University
2 Yenphong Medical Center
3 Bac Giang General Hospital
4 Duc Giang General Hospital
5 Hanoi University of Public Health

Nội dung chính của bài viết

Tóm tắt

Lung cancer, the most common cause of cancer death worldwide, with most patients dying from distant metastases, has become increasingly complex in achieving effective treatment. In lung cancer, particularly in non-small-cell lung cancer (NSCLC), EGFR, ALK, RET, ROS1, BRAF, KRAS, NRAS, NTRK, PIK3CA,
DDR2, MET, and ERBB2 have been reported as key oncogenic drivers, which have led to the development and application of targeted therapeutic drugs aimed at these dysfunctional genes. Personalized medicine based on these oncogenic drivers offers the greatest potential benefit in the diagnosis and treatment of NSCLC patients. In particular, personalized medicine is importantly recommended for the treatment of advanced NSCLC. Here, we briefly summarize the significant application of personalized medicine based on key oncogenic drivers for the diagnosis and treatment of NSCLC with targeted therapeutic drugs, both globally and Vietnam.

Chi tiết bài viết

Từ khóa

Personalized medicine, targeted therapy, lung cancer, non-small-cell lung cancer (NSCLC), diagnosis, treatment

Tài liệu tham khảo

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global caner statistics 2020: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.
2. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-smallcell lung cancer: Implications for current and future therapies. J Clin Oncol 31(8): 1039-1049, 2013.
3. https://www.medznat.ru/en/practice/medicalbilling/precision-and-personalized-medicineunlocking-the.
4. Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 12: 22, 2013.
5. Xue Y, Hou S, Ji H, and Han X: Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance. Protein Cell 8(3): 178-190, 2017.
6. Du X, Shao Y, Qin HF, Tai YH and Gao HJ. ALK-rearrangment in non-small-cell lung cancer (NSCLC). Thorar Cancer. 9(4): 423-430, 2018.
7. Gainor JF and Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 18(7): 865-975, 2013.